15996 Federal Register / Vol. 74, No. 66 / Wednesday, April 8, 2009 / Notices 

March 31, 2010. This service area will 

be included in the upcoming 

competition for the Part C HIV Early 

Intervention Services for project periods 

starting April 2010. 

FOR FURTHER INFORMATION CONTACT: 

Maria C. Rios, via e-mail 

mrios@hrsa.gov, or via telephone, 301– 

443–0493. 

Dated: April 2, 2009. 

Marcia K. Brand, 

Acting Deputy Administrator. 

[FR Doc. E9–7963 Filed 4–7–09; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Substituted Triazine and Purine 

Compounds for the Treatment of 

Chagas Disease and African 

Trypanosomiasis 

Description of Invention: Parasitic 

protozoa are responsible for a wide 

variety of infections in both humans and 

animals. Trypanosomiasis poses health 

risks to millions of people across 

multiple countries in Africa and North 

and South America. Visitors to these 

regions, such as business travelers and 

tourists, are also at risk for contracting 

parasitic diseases. There are two types 

of African trypanosomiasis, also known 

as sleeping sickness. One type is caused 

by the parasite Trypanosoma brucei 

gambiense, and the other is caused by 

the parasite Trypanosoma brucei 

rhodesiensi. If left untreated, African 

sleeping sickness results in death. 

Chagas disease, caused by Trypanosoma 

cruzi (T. cruzi), affects millions of 

people in Mexico and South and Central 

America. Untreated, Chagas disease 

causes decreased life expectancy and 

can also result in death. 

The subject invention provides for 

novel triazine and purine compounds 

that are useful for the treatment and 

prevention of mammalian protozoal 

diseases, including African 

trypanosomiasis, Chagas disease and 

other opportunistic infections. The 

compounds can inhibit the cysteine 

proteases rhodesain found in the 

parasites that cause African 

trypanosomiasis and cruzain found in T. 

cruzi. The invention includes 

composition claims for the novel 

triazine and purine compounds, 

methods for inhibiting cruzain or 

rhodesain in a subject, and methods for 

treating subjects suffering from African 

trypanosomiasis or Chagas disease. 

Applications: Prophylactic and 

therapeutic treatment of African 

trypanosomiasis and Chagas disease. 

Advantages: Novel compounds 

against the cysteine proteases, cruzain 

and rhodesain; Compounds possess low 

nanomolar inhibitory potential against 

cruzain and rhodesain. 

Development Status: In vitro and in 

vivo data are available upon request and 

upon execution of an appropriate 

confidentiality agreement. 

Inventors: Craig J. Thomas et al. 

(NHGRI). 

Patent Status: U.S. Provisional 

Application No. 61/199,763 filed 19 

Nov 2008 (HHS Reference No. E–267– 

2008/0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIH Chemical Genomics Center 

(NCGC) is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize appropriate lead 

compounds described in U.S. 

Provisional Application No. 61/199,763. 

Please contact Dr. Craig J. Thomas 

(craigt@nhgri.nih.gov) or Claire Driscoll 

(cdriscol@mail.nih.gov), Director of the 

NHGRI Technology Transfer Office, for 

more information. 

Improved Expression Vectors for 

Mammalian Use 

Description of Invention: This 

technology relates to improving levels of 

gene expression using a combination of 

a constitutive RNA transport element 

(CTE) with a mutant form of another 

RNA transport element (RTE). The 

combination of these elements results in 

a synergistic effect on stability of mRNA 

transcripts, which in turn leads to 

increased expression levels. Using HIV– 

1 gag as reporter mRNA, one mutated 

RTE in combination with a CTE was 

found to improve expression of unstable 

mRNA by about 500-fold. Similarly this 

combination of elements led to 

synergistically elevated levels of HIV–1 

Env expression. The function of CTEs 

and RTEs is conserved in mammalian 

cells, so this technology is a simple and 

useful way of obtaining high levels of 

expression of otherwise poorly 

expressed genes and can be used in a 

number of applications such as but not 

limited to improvements of gene 

therapy vectors, expression vectors for 

mammalian cells. 

Applications: Gene therapy; DNA 

vaccines; Protein expression. 

Development Status: In vitro data 

available. 

Inventor: Barbara K. Felber et al. 

(NCI). 

Patent Status: U.S. Utility Application 

No. 10/557,129 filed 16 Nov 2005, from 

PCT Application No. PCT/US04/15776 

filed 19 May 2004, which published as 

WO 2004/113547 on 29 Dec 2004 (HHS 

Reference No. E–223–2003/1–US–03). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute Vaccine 

Branch is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Please 

contact John D. Hewes, Ph.D. at 301– 

435–3121 or hewesj@mail.nih.gov for 

more information. 

Dated: April 1, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–7883 Filed 4–7–09; 8:45 am] 

BILLING CODE 4140–01–P 


rwilkins on PROD1PC63 with NOTICES